Domestic price of Alpelisib-Piqray

Alpelisib - Piqray is used in combination with fulvestrant for the treatment of hormone receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, advanced or metastatic breast cancer that develops during or after endocrine-based therapy in postmenopausal women and men with an FDA-approved diagnostic test such as therascreen PIK3CA RGQ PCR Kit) detects tumors containing mutations in the catalytic phosphatidylinositol-3-kinase subunit alpha (PIK3CA).

The recommended dose of Apelvis is 300 mg once daily, usually requiring dose reduction to 250 and 200 mg daily, but lower doses are not recommended. Apelvis is administered in combination with the anti-estrogen fulvestrant at a recommended dose of 500 mg intramuscularly on days 1, 15 and 29, and once a month thereafter. Side effects of apelvis-fulvestrant combination therapy are common and occur in nearly all patients and include hyperglycemia, diarrhea, nausea and vomiting, decreased appetite, fatigue, rash, stomatitis, weight loss, and increased serum creatinine, lipase, and transaminases levels.

The original drug of Apellis is not marketed in the country and therefore cannot be included in medical insurance. There are European and Indian versions of the original Apelvis drug sold overseas. The ingredients are basically the same. The price of the European version of 150mg*56 tablets per box may be more than 4 RMB 40,000 ( (The price may fluctuate due to the exchange rate), The price of the Indian version150mg*28 tablets per box may be more than 5,000 yuan (the price may fluctuate due to the exchange rate). There are currently no generic versions of Apelvis produced and marketed.